Attached files
| file | filename |
|---|---|
| EX-21.1 - EX-21.1 - AGIOS PHARMACEUTICALS, INC. | d113932dex211.htm |
| EX-31.2 - EX-31.2 - AGIOS PHARMACEUTICALS, INC. | d113932dex312.htm |
| EX-31.1 - EX-31.1 - AGIOS PHARMACEUTICALS, INC. | d113932dex311.htm |
| EX-32.2 - EX-32.2 - AGIOS PHARMACEUTICALS, INC. | d113932dex322.htm |
| EX-32.1 - EX-32.1 - AGIOS PHARMACEUTICALS, INC. | d113932dex321.htm |
| EX-10.25 - EX-10.25 - AGIOS PHARMACEUTICALS, INC. | d113932dex1025.htm |
| EX-10.13 - EX-10.13 - AGIOS PHARMACEUTICALS, INC. | d113932dex1013.htm |
| 10-K - FORM 10-K - AGIOS PHARMACEUTICALS, INC. | d113932d10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-201796, 333-193802 and 333-190101 and Form S-3 No. 333-200822) of Agios Pharmaceuticals, Inc. of our reports dated February 26, 2016 with respect to the consolidated financial statements of Agios Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Agios Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2015.
/s/ Ernst & Young LLP
Boston, Massachusetts
February 26, 2016